Antiangiogenesis therapeutic strategies in prostate cancer

Cancer and Metastasis Reviews

Volumn 21, Issue 1, 2002, Pages 93-106

  Macpherson, Gordon R ^a   Ng, Sylvia S W ^a   Lakhani, Nehal J ^a   Price, Douglas K ^a   Venitz, Jurgen ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

2 methoxyestradiol; Angiogenesis; Carboxyamido triazole; Endostatin; Prostate cancer; Thalidomide

Indexed keywords

2 METHOXYESTRADIOL; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOCETAXEL; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 10; INTERLEUKIN 8; MASPIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADVANCED CANCER; ANESTHESIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CLINICAL TRIAL; DRUG POTENTIATION; GAIT DISORDER; HUMAN; MENTAL DISEASE; METASTASIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RESTLESSNESS; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 0036399621     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020128708223     Document Type: Review

References (145)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1, 1999
2. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240, 1941
3. Montgomery JS, Price DK, Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146, 2001
4. Stewart RJ, Panigrahy D, Flynn E, Folkman J: Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688-693, 2001
5. Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD: The androgen receptor: Genetic considerations in the development and treatment of prostate cancer. J Mol Med 77: 419-426, 1999
6. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35: 63-70, 1998
7. The Veterans Administration Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967
8. Scott WW, Menon M, Walsh PC: Hormonal therapy of prostatic cancer. Cancer 45: 1929-1936, 1980
9. Koivisto P, Visakorpi T, Kallioniemi OP: Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226: 57-63, 1996
10. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989
11. Group TCAS: A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. Cancer Treat Res 59: 29-40, 1992
12. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995
13. Nehls V, Schuchardt E, Drenckhahn D: The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc Res 48: 349-363, 1994
14. Cockerill GW, Gamble JR, Vadas MA: Angiogenesis: Models and modulators. Int Rev Cytol 159:113-160, 1995
15. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000
16. Choy M, Rafii S: Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 19: 181-191, 2001
17. Sokoloff MH, Chung LW: Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev 17: 307-315, 1999
18. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993
19. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989
20. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993
21. McNamara DA, Harmey JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ: Significance of angiogenesis in cancer therapy. Br J Surg 85: 1044-1055, 1998
22. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD: Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther 292: 31-37, 2000
23. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995
24. Suh DY: Understanding angiogenesis and its clinical applications. Ann Clin Lab Sci 30: 227-238, 2000
25. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994
26. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92: 4562-4566, 1995
27. Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. European J Clin Pharmacol 57: 365-376, 2001
28. Kruger EA, Figg WD: TNP-470: An angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 9: 1383-1396, 2000
29. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD: Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 268: 183-191, 2000
30. Pribluda VS, Gubish ER, Lavallee TM, Treston A, Swartz GM, Green SJ: 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19: 173-179, 2000
31. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996
32. Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi JI, Naito S, Nozaki C, Iwanaga S, Kuwano M: Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275: 38912-38920, 2000
33. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991
34. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995
35. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999
36. Izawa JI, Dinney CP: The role of angiogenesis in prostate and other urologic cancers: A review. CMAJ 164: 662-670, 2001.
37. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51: 161-167, 1998
38. Greene G, Kitadai Y, Pettaway C, von Eschenbach A, Bucana, C, Fidler I: Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150: 1571-1582, 1997
39. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar_Eli M, Radinsky, R, Pettaway CA, Dinney CP: Interleukin 8 expression regulates tumori-genicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119, 2000
40. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878: 236-270, 1999
41. Figg WD, Dahut W, Duray P. Hamilton, M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7: 1888-1893, 2001
42. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut W: A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28: 62-66, 2001
43. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU: Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198-1203, 2001
44. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E: A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 5: 2324-2329, 1999
45. Diggle GE: Thalidomide: 40 years on. IJCP 55:627-631, 2001
46. McBride W: Thalidomide and congenital abnormalities. Lancet 2: 1358, 1961
47. Lenz W: Thalidomide and congenital abnormalities. Lancet 1: 45, 1962
48. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Therapeut 6: 303-306, 1965
49. Calabrese L, Fleischer AB: Thalidomide: Current and potential clinical applications. Am J Med 108: 487-495, 2000
50. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834, 1998
51. Jorizzo JL, Schmalstieg FC, Solomon AR, Cavallo T, Taylor RS, Rudloff HB, Schmalstieg EJ, Daniels JC: Thalidomide effects in Behcet’s syndrome and pustular vasculitis. Arch Intern Med 146: 878-881, 1986
52. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326: 1055-1058, 1992
53. Parker PM, Chao N, Nademanee A, O_Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE: Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86: 3604-3609, 1995
54. Makonkawkeyoon S, Limson_Pobre RN, Moreira AL, Schauf V, Kaplan G: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90: 5974-5978, 1993
55. Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C: Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 126: 923-927, 1990
56. Thomas DA, Kantarjian HM: Current role of thalidomide in cancer treatment. Curr Opin Oncol 12: 564-573, 2000
57. D’ Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994
58. Kenyon BM, Browne F, D_Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64: 971-978, 1997
59. Turk BE, Jiang H, Liu JO: Binding of thalidomide to alphal-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552-7556, 1996
60. Singhal S, Mehta J: Thalidomide in cancer: Potential uses and limitations. BioDrugs 15: 163-172, 2001
61. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492-494, 2001
62. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75: 897-901, 2000
63. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 18: 2593-2602, 2000
64. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708-715, 2000
65. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME: Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82: 812-817, 2000
66. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85: 953-958, 2001
67. Ginsburg PM, Dassopoulos T, Ehrenpreis ED: Thalidomide treatment for refractory Crohn’s disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med 33:516-525, 2001
68. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neuro-Oncology 54:31-38, 2001
69. Stirling D: Thalidomide: A novel template for anticancer drugs. Semin Oncol 28: 602-606, 2001
70. Beckner ME: Factors promoting tumor angiogenesis. Cancer Invest 17: 594-623, 1999
71. Thomas DA, Kantarjian HM: The revitalization of thalidomide. Ann Oncol 12: 885-886, 2001
72. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703, 1991
73. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675-1680, 1993
74. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I: Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 40:11-20, 1998
75. Joseph IB, Isaacs JT: Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 90: 1648-1653, 1998
76. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD: Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br J Cancer 78: 336-343, 1998
77. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K: Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality 8: 390-396, 1996
78. Hoglund P, Eriksson T, Bjorkman S: A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 26: 363-383, 1998
79. Eriksson T, Bjorkman S, Roth B, Hoglund P: Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol 52: 807-817, 2000
80. Stephens TD, Fillmore BJ: Hypothesis: Thalidomide embryopathy-proposed mechanism of action. Teratology 61: 189-195, 2000
81. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59: 1489-1499, 2000
82. Haslett PA, Corral LG, Albert M, Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892, 1998
83. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H: Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haem 115: 605-608, 2001
84. Fujita J, Mestre JR, Zweldis JB, Subbaramaiah K, Dannenberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7: 3349-3355, 2001
85. Yamada M, Kawai M, Kawai Y, Mashima Y: The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 19: 300-304, 1999
86. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577, 1999
87. Kirschenbaum A, Liu X, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology 58: 127-131, 2001
88. Hess S, Akermann MA, Whendt S, Zwingenberger K, Eger K: Synthesis and immunological activity of water-soluble thalidomide prodrugs. Bioorg Med Chem 9: 1279-1291, 2001
89. Kandel J, Bossy-Wetzel E, Radvany F, Klagsburn M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095-1104, 1991
90. Chen C, Parangi S, Tolentino M, Folkman J: A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55: 4230-4233, 1995
91. Good D, Polverini P, Rastinejad F, LeBeau M, Lemons R, Frazier W, Bouck N: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Nat Acad Sci USA 87: 6624-6628, 1990
92. O’Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell 79: 315-328, 1994
93. O’Reilly M, Boehm T, Shing Y, Fuakai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997
94. O’Reilly M, Pirie-Shepard S, Lane W, Folkman J: Antiangiogenic activity of a cleaved conformation of the serpin antithrombin. Science 285: 1926-1928, 1999
95. Yamiguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen B: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18: 4414-4423, 1999
96. Dhanabal M, Ramchandran R, Volk R, Stillman I, Lombardo M, Iruela-Arispe M, Simons M, VP S: Endostatin. Yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197, 1999
97. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger H, Chiarugi V, Ramponi G: Inhibitory effect of full-length human endostatinon in vitro angiogenesis. Biochem Biophys Res Commun 263: 340-345, 1999
98. Boehm T, Folkman J, Browder T, O’Reilly M: Antiangiogenic therapy of experimental cancer does not induce acquired drug reisistance. Nature 390: 404-407, 1997
99. Yokoyama Y, Dhanabal M, Griffioen A, Sukhatme V, Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196, 2000
100. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J, Chen L: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60: 1793-1796, 2000
101. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme V: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 258: 345-352, 1999
102. Sim B, Fogler W, Zhou X, Liang H, Madsen J, Luu K, O’Reilly M, Tomaszewski J, Fortier A: Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3: 41-51, 1999
103. Kisker O, Becker C, Prox D, Fannon M, D’Amato R, Flynn E, Fogler W, Sim B, Allred E, Pirie-Shepard S, Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump inproves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61: 7669-7674, 2001
104. Yokoyami Y, Green J, Sukhatme V, Ramakrishnan S: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model. Cancer Res 60:2000
105. Hasle H, Clemmensen I, Mikkelsen M: Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355: 165-169, 2000
106. Iughetti P, Suzuki O, Godoi P, Alves V, Sertie A, Zorick T, Soares F, Camargo A, Moreira E, di Loreto C, Moreira-Filho A, Simpson A, Oliva G, Passos-Bueno M: A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:2001
107. Kohn EC, Liotta LA: L651582: A novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82: 54-60, 1990
108. Kohn EC, Sandeen MA, Liotta LA: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52: 3208-3212, 1992
109. Lambert PA, Somers KD, Kohn EC, Perry RR: Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. Surgery 122: 372-378; discussion 378-379, 1997
110. Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL, Schellhammer PF: Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 68: 259-264, 1996
111. Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML, Kohn EC: Inhibitory effects of CAI in glioblastoma growth and invasion. J Neuro-Oncology 32: 93-101, 1997
112. Qin LX, Tang ZY, Li XM, Bu W, Xia JL: Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. Ann Acad Med Singapore 28: 147-151, 1999
113. Gusovsky F, Lueders JE, Kohn EC, Felder CC: Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown. J Biol Chem 268: 7768-7772, 1993
114. Felder CC, Ma AL, Liotta LA, Kohn EC: The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 257: 967-971, 1991
115. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler_Stevenson WG, Liotta LA: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511, 1994
116. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA: Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92:1307-1311, 1995
117. Alessandro R, Masiero L, Lapidos K, Spoonster J, Kohn EC: Endothelial cell spreading on type IV collagen and spreading-induced FAK phosphorylation is regulated by Ca2+ influx. Biochem Biophys Res Commun 248: 635-640, 1998
118. Ge S, Rempel SA, Divine G, Mikkelsen T: Carboxyamidotriazole induces apoptosis in bovine aortic endothelial and human glioma cells. Clin Cancer Res 6: 1248-1254, 2000
119. Waselenko J, Shinn C, Willis C, Flinn I, Grever M, Byrd J: Carboxyamido-triazole (CAI) - a novel ‘static’ signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. Leuk Lymph 42: 1049-1053, 2001
120. Figg WD, Cole KA, Reed E, Steinberg SM, Piscitelli SC Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B: Pharmacokinetics of orally administered carboxyamidotriazole, an inhibitor of calcium-mediated signal transduction. Clin Cancer Res 1: 797-803, 1995
121. Ludden L, Strong J, Kohn E, Collins J: Similarity of metabolism of CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo. Clin Cancer Res 1: 399-405, 1995
122. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56: 569-573, 1996
123. Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed, E: Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 15: 1985-1993, 1997
124. Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick_Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA: A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 7: 1600-1609, 2001
125. Berg FD, Kuss E: Serum concentration and urinary excretion of ‘classical’ estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy. Arch Gynecol Obstet 251: 17-27, 1992
126. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368: 237-239, 1994
127. Klauber N, Parangi S, Flynn E, Hamel E, D_Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997
128. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ: 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51: 951-962, 1997
129. Nicosia RF, Ottinetti A: Growth of microvessels in serumfree matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63:115-122, 1990
130. Wassberg E: Angiostatic treatment of neuroblastoma. Ups J Med Sci 104: 1-24, 1999
131. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493-499, 1999
132. Shang W, Konidari I, Schomberg DW: 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: A potential follicular antiangiogenic regulator. Biol Reprod 65: 622-627, 2001
133. Miller KD, Haney LG, Pribluda VS, Sledge GW: A phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol (2ME2) in patients (Pts) with refractory metastatic breast cancer (MBC). American Society of Clinical Oncology (Abstract # 170), 2001
134. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R: The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91-97, 1997
135. Miki T, Nonomura N, Nozawa M, Harada Y, Nishimura K, Kojima Y, Takahara S, Okuyama A: Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line. J Urol 160: 210-213, 1998
136. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53: 5233-5236, 1993
137. Kim J, Logothetis CJ: Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26: 281-290, 1999
138. Gibaldi M: Regulating angiogenesis: a new therapeutic strategy. J Clin Pharmacol 38: 898-903, 1998
139. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles_Gerte E, McDonnell T, D_Amato R: Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 93: 208-213, 2001
140. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD: Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79:1588-1593, 1999
141. Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Me 6: 196-199, 2000
142. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M: Role of interleukin 10 and transforming growth factor betal in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5: 711-720, 1999
143. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI: Tumor angiogenesis is associated with MUCI overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 7: 1533-1538, 2001
144. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S: Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55: 1687-1690, 1995
145. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, Dong Z: Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 8: 497-505, 2001